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Background. Between September 20, 1995 and Sep-
tember 20, 1997,208 adult patients undergoing renal 
transplantation were randomized to receive tacroli-
mus/prednisone (n=106) or tacrolimus/prednisone/my-
cophenolate mofetil (n=102), with the goal of reducing 
the incidence of rejection. 
Methods. The mean recipient age was 50.7 ± 13.7 years. 
Sixty-three (30.3%) patients were 60 years of age or older 
at the time of transplantation. The mean donor age was 
34.5±21.7 years. The mean cold ischemia time was 
lJO.5±9.2 hr. The mean follow-up is 15±7 months. 
Results. The overall I-year actuarial patient survival 
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was 94%; the ov~rall I-year actuarial graft survival 
was 87%. When the patient and graft survival data 
were stratified to recipients under the age of 60 who 
did not have delayed graft function, the overall I-year 
actuarial patient survival was 97%, and the corre-
sponding I-year actuarial graft survival was 93%. 
There were no differences between the two groups. 
The overall incidence of rejection was 36%; in the dou-
ble-therapy group, it was 44%, whereas in the triple 
therapy group, it was 27% (P=0.OI4). The mean serum 
creatinine was 1.6±0.8 mgldl. A total of 36% of the 
successfully transplanted patients were taken off 
prednisone; 32% of the patients were taken off antihy-
pertensive medications. The incidence of delayed 
graft function was 21%, the incidence of cytomegalo-
virus was 12.5%, and the initial and final incidences of 
posttransplant insulin-dependent diabetes mellitus 
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were 7.0% and 2.9%; again, there was no difference 
between the two groups. 
Conclusions. This trial suggests that the combina-
tion of tacrolimus, steroids, and mycophenolate 
mofetil is associated with excellent patient and graft 
survival and a lower incidence of rejection than th~ 
combination of tacrolimus and steroids. 
With the increasing accumulation of data regarding its use 
in renal transplantation (1-10), tacrolimus has become ac-
cepted as an effective immunosuppressive agent. However, 
the optimal manner in which it should be used has not yet 
been established. One question has concerned the utility of 
an adjunctive third agent. In an earlier trial comparing two 
tacrolimus-based regimens, with and without azathioprine, 
triple therapy was associated with a not-quite-significant 
reduction in the incidence of acute rejection, 45% vs. 55%, but 
worse graft survival, 76% vs. 84% in the double-therapy 
group, at 3 years (3, 11). Subsequent to the completion of that 
trial, mycophenolate mofetil (MMF*; CellCept) was approved 
by the Food and Drug Administration (12-15), and a new, 
prospective randomized trial was begun, comparing tacroli-
mus/prednisone with tacrolimusiprednisone!MMF. The first 
report ofthis trial suggested a lower incidence of rejection in 
the triple-therapy group, without differences in patient or 
graft survival (16). In this report, we present I-year actuarial 
data, in a larger number of patients, which confirm these 
original observations. 
PATIENTS AND METHODS (TABLE 1) 
Between September 20, 1995, and September 20,1997,208 renal 
transplantations, in 206 patients, were performed in adult recipients 
of first or second cadaveric kidneys only, who consented to partici-
pate in the trial. One hundred six were randomized to receive ta-
crolimus and prednisone, and 102 were randomized to receive ta-
crolimus, prednisone, and MMF, without induction antilymphocyte 
antibody therapy. Living donor recipients, patients undergoing their 
third or greater transplant, patients receiving an additional organ 
(e.g., pancreas, islets, liver, and/or bone marrow), patients refusing 
to consent, and pediatric recipients were excluded from the trial. The 
mean recipient age was 50.7::!: 13.7 years (range: 19-84). Thirty-one 
(14.9%) patients were undergoing retransplantation, and 11 (5.3%) 
had a panel-reactive antibody level over 40%. Sixty-three (30.3%) 
patients were 60 years of age or older at the time of transplantation. 
Sixteen (7.7%) patients had undergone previous liver (13) or heart (3) 
transplantation. The mean donor age was 34.5::!:21.7 years (range: 
0.01-76.5). Twenty-five (12%) transplants were with pediatric en-
bloc kidneys from donors less than 4 years of age, ana 28 (13.5%) 
were with kidneys from donors 60 years of age or older. The mean 
cold ischemia time was 30.5::!:9.2 hr (range: 4.5-57.1). The mean 
number of matches and mismatches was 2.5::!:1.4 and 3. I::!: 1.5; there 
were 17 (8.2%) 0 antigen mismatch cases. There were no significant 
differences between the two arms in any of these parameters, except 
for a slightly ~lder mean recipient age in the double-therapy arm 
(52.5::!:13.3 years vs. 48.7::!:13.6 years, P<0.05) and a slightly longer 
mean cold ischemia time in the triple therapy group (32.2::!:9.5 hr vs. 
28.8::!:8.7 hr, P<O.02). 
Tacrolimus dosing (Table 2). All patients received tacrolimus 
(0.15 mg/kg orally) on call to the operating room. Postoperatively, 
intravenous tacrolimus (0.025-0.05 mglkg/day as a continuous infu-
sion) was begun in the recovery room. Patients were converted to oral 
tacrolimus (0.15 mg/kg twice daily) as soon as they were able to 
tolerate oral dosing, generally within 2-3 days. Target levels were 
* Abbreviations: MMF, mycophenolate mofetil; PTDM, posttrans-
plant diabetes mellitus. 
20-25 ng/ml whole blood by IMX for the first 2 weeks after trans. 
plantation, 15-20 ng/ml by 1 month, 10-15 ng/ml by 3 months, and 
5-12 ng/ml chronically. The target levels were the same in both 
groups. 
Steroid dosing. All patients received a 1000-mg bolus of intrave_ 
nous methylprednisolone in the operating room, and a short steroid 
recycle, from 200 to 20 mg/day, of intravenous methylprednisolone or 
oral prednisone, during the first 6 days after transplantation. In the 
ideal scenario, the prednisone dose was decreased to 15 mg/day by 
3-4 weeks after transplantation, and then by 2.5 mg/day decrements 
to 10 mg/day by 2-3 months. Further tapering was individualized, 
but generally followed the schedule of 1.25-2.5 mg/day decrements 
every 4-6 weeks, with the protocol-defined goal of discontinuing 
steroids in all patients. In practice, the development of early «1 
month) acute rejection slowed down the timetable for steroid taper. 
ing, but steroid withdrawal remained the routine goal. Patients who 
developed rejection at low doses of prednisone (5-7.5 mg/day) neces-
sarily received an increase in their steroid dosage as part of the 
treatment for rejection, but here also the possibility of complete 
steroid withdrawal was not necessarily obviated. Generally, no more 
than two attempts were made to withdraw steroids. 
Mycophenolate mofetil. Patients randomized to the triple-therapy 
group were given 1 g of MMF orally before transplantation, and 1 g 
orally twice daily postoperatively. The dose was cut in half if a 
patient developed symptoms of toxicity, e.g., diarrhea. If symptoms 
did not respond to a decrease in the dosage, MMF was discontinued. 
MMF and tacrolimus doses were separated by 2-4 hr within a few 
months of the initiation of the trial, to allow for greater tolerability 
of the combination of the two agents. 
Rejection. Rejection was biopsy-proven in over 95% of cases and 
was treated initially with a 1000-mg bolus and recycle of steroids, 
and an increase in the tacrolimus dose. Ster.oid-resistant rejections 
were treated with antilymphocyte preparations, generally OKT3, but 
occasionally ATG. Patients randomized to double therapy could be 
crossed over to triple therapy if they developed steroid-resistant or 
mild-moderate (or greater) rejection, at the discretion ofthe treating 
physician. Occasionally, refractory rejection was treated with intra-
venous immunoglobulin (2 glkg) in 7-10 divided doses, again at the 
discretion of the treating physician (17, 18). 
Although all of the agents utilized in this trial were approved by 
the Food and Drug Administration, because of its randomized na-
ture, approval from the Institutional Review Board of the University 
of Pittsburgh was obtained, with yearly renewals. 
Statistical analysis (19). Continuous variables are presented as 
mean ::!: standard deviation, and categorical variables as proportions. 
Randomization was done by sequential draw of assignment using 
a variable block randomization scheme. The block sizes varied (4 or. 
• 6) and were selected with equal probability. The order of assignment 
within a block was determined by generating a random number 
between 0 and 1 and then rearranging the random numbers in 
ascending order. 
Baseline characteristics of the patient population were compared 
using the standard two-sample t test for continuous data and Pear-
son's chi-square test for categorical data. 
Patient survival was calculated from the date of kidney transplan-
tation until death and graft survival from the date of kidney trans-
plantation until graft failure, repeat transplantation, or patient 
death. Survival curves were generated using the Kaplan-Meier 
(product-limit) method (20) and compared by the log-rank (Mantel-
Cox) test (21). All tests were two-tailed. AP-value less than 0.05 was 
considered statistically significant. All analyses were performed us-
ing SPSS for Windows software. 
The data were analyzed by intention to treat for all patients in the 
trial. In addition, patient and graft survival data were calculated for 
recipients under 60 years of age who did not have delayed graft 
function. This subgroup analysis was performed to facilitate compar· 
ison with large multicenter trials, the entry criteria for which often 
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TABLE 1. Recipient and donor demographics" 
TacrolimuslPrednisone TacroJim uslPrednisonelMMF Overall 
N 
Recipient age (yr) 
(Range) 
Repeat transplantation 
PRA >40% 
>60 yr . 
Previous liver or heart transplant 
Donor age (yr) 
(Range) 
2::60 yr 
<4yr 
(En bloc) 
Cold ischemia time 
(Range) 
Antigen match 
Antigen mismatch 
o Antigen mismatch 
" *, P < 0.05; **, P < 0.02. 
TABLE 2. Immunosuppressiona 
Tacrolimus 
0.15 mg/kg orally 
106 
52.5::13.3 
(19.3-84.1) 
13 (12.2%) 
6 (5.7%) 
36 (34.0%) 
7 (6.6%) 
33.8=20.9 
(0.2-76.4) 
12 (11.3%) 
14 (13.2%) 
28.8=8.7 
(4.2--49.0) 
2.4=1.4 
3.2=1.5 
6(5.7%) 
Preoperative 
Postoperative 0.025-0.05 mg/kg intravenously, 
continuous infusion, until tolerating 
orally, then 0.15 mg/kg orally twice a day 
Target levels (ng/ml whole blood I.MX) 
First 2 weeks 20-25 
1 month 15-20 
3 months 10-15 
Chronically 5-12 
Steroids (intravenous methylprednisolone o"r po prednisone) 
Intraoperative 1000 mg 
POD 1-6 200 ~ 20 mg/day 
3-4 we~ks 15 mg/day, then 2.5 mg/d decrement to 
2-3 months 10 mg/day, then 
Every 4-6 weeks 1.25-2.5 mg/day decrement, to 0 mg/day, if 
possible 
Mycophenolate mofetil 
Preoperative 1000 mg orally 
Postoperative 1000 mg orally twice a day 
a I.MX, POD, postoperative day. 
.have been restricted to patients under 60 years of age who have. 
functioning allografts. 
RESULTS (TABLE 3) 
The mean follow-up was 15±7 months. The overall I-year 
actuarial patient survival was 94%; in the stratified group, it 
was 97%. There was no difference between the double- and 
triple-therapy arms in either the overall or the stratified group. 
The overall I-year actuarial graft survival was 87%; in the 
stratified group, it was 93%. Again, there was no difference 
between the two arms in either the overall or the stratified 
group. 
The overall incidence of rejection and steroid-resistant rejec-
tion was 36% and 5.3%; in the double-therapy arm, it was 44% 
and 7.5%, and in the triple-therapy arm, it was 27% (P=0.014) 
and 2.9% (P=NS). Rejections were histologically somewhat 
more severe in the double-therapy group, although the differ-
102 
48.7=13.6* 
(18.8-72.5) 
18 (17.6%) 
5(4.9%) 
27 (26.5%) 
9 (8.8%) 
35.5=22.6 
(0.01-76.5) 
16 (15.7%) 
11 (10.8%) 
32.2=9.5** 
(15.3-57.1) 
2.6=1.4 
3.l:!: 1.5 
11 (10.8%) 
208 
50.7=13.7 
(18.7-84.1) 
31 (14.9%) 
11 (5.3%) 
63 (30.3%) 
16 (7.7%) 
34.5=21.7 
(0.01-76.5) 
28 (13.5%) 
25 (12.0%) 
30.5=9.2 
(4.7-57.1) 
2.5=1.4 
3.1=1.5 
17 (8.2%) 
ences were not statistically different (Table 4; the pathologists 
were blinded as to the randomization status of each patient). In . 
the triple-therapy patients who never discontinued MMF, the 
incidence of rejection and steroid-resistant rejection was 16% 
and 1.5%, whereas in those who discontinued MMF at any time, 
it was 49% and 5.7%. Most (80%) rejection episodes occurred 
within the first month after transplantation, in either group, 
and within the triple-therapy group, in either subgroup (i.e. 
those remaining on MMF or those discontinuing MMF). 
At most recent follow-up, the mean serum creatinine was 
1.6±0.8 mg/dl and did not differ between the two arms. The 
mean tacrolimus dose was 8.7±6.6 mg/day, 8.4±6.0 mg/day 
in the double-therapy arm, and 9.0±7.1 mg/day in the triple-
therapy arm (P=NS). The mean tacrolimus level was 1O.0±4.4 
ng/ml, again without differences between the two arms. The 
lack of difference between the two groups was not surprising, as 
the protocol dosing and target levels were designed to be simi-
lar. The mean MMF dose was 1142±493 mgiday in the MMF arm. 
A total of 36% of successfully transplanted patients were 
withdrawn from steroids, and 32% were withdrawn from 
antihypertensive medications. The mean serum cholesterol 
was 196±55 mg/dl. There were no differences between the 
two arms for any of these parameters. 
The incidence of delayed graft function was 21%, and the 
incidence of cytomegalovirus, including asymptomatic infection, 
was 12.5%. The incidence of post transplant lymphoproliferative 
disorder was 0.5%. The initial and final incidences of insulin-
dependent posttransplant diabetes mellitus (PTDM) was 7.0% 
and 2.9%. Again, there were no differences between the double-
and triple-therapy arms with regard to these adverse events. 
Cross-over occurred in 31% of cases, 28% from double to 
triple therapy, and 34% from triple to double therapy. In the 
second year ofthe trial, the incidence of cross-over from triple 
to double therapy was 12%. 
DISCUSSION. 
This report presents I-year actuarial outcomes from the first 
randomized evaluation of MMF with tacrolimus-based therapy 
in renal transplant recipients. It confirms data reported with 
cyclosporine-based regimens, that MMF is associated with a 
significant reduction in the incidence of rejection, without any 
I I 
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TABLE 3 .. Results 
Follow .. up at 15:'::7 months 
Tacrolimus/prednisone TacrolimusiprednisonelMMF 9verall --------------~~--------~--~~-
I-year actuarial patient survival (whole group) 
I-year actuarial patient survival (stratified group) 
I-year actuarial graft survival Ewhol~ group) 
I-year actuarial graft survival (stratified group) 
Rejection 
Steroid-resistant rejection 
Serum creatinine (mg/dl) 
Tacrolimus dose (mg/day) 
Tacrolimus level (ng/m!) 
Off steroids 
Off antihypertensive medications 
Cholesterol (mg/d!) 
Cytomegalovirus 
Posttransplant lymphoproliferative disorder 
Delayed graft function 
PTDM 
Initial 
Final 
Cross-over 
a p = 0.014. 
Borderline 
Banff 
lA 
IB 
Banff 2 
No biopsy 
TABLE 4. Severity of rejectionU 
Tacrolimuslprednisone 
5 (11 %) 
16 (36%) 
4 (9%) 
19 (43%) 
3 
a Percentages are calculated within groups. 
Tacrolimusl 
prednisoneIMMF 
5 (19%) 
11 (41%) 
4 (15%) 
7 (26%) 
1 
early difference in patient or graft survival (12-15). Although 
there was an increase in the incidence of cytomegalovirus in the 
triple-therapy group, this did not reach statistical significance. 
Patient and graft survival were analyzed for both the en-
tire group and a stratified group that excluded recipients 
over 60 years of age or who had delayed graft function. The 
stratification was made to allo~ for a comparison of primary 
outcomes with those from large multicenter trials, whose 
entry criteria generally exclude patients over 60 years of age 
or who have delayed graft function (8, 9, 13, 14). A substan-
tial number of the patie'hts entered into this trial were over 
60 years of age, and, although this age group has been asso-
ciated with acceptable outcomes, there has been a slightly 
higher mortality when compared with recipients under the 
age of 60 (22-25). Similarly, patients with delayed graft 
function are known to have worse graft survival than pa-
tients without delayed graft function (26, 27). When the 
stratified group was analyzed, I-year actuarial patient and 
graft survivals of 97% and 93% were observed, comparable to 
those seen in the large multicenter trials (8, 9, 13, 14). 
It is worth noting that there was no difference in tacroli-
mus dosing between the two arms. To some extent, this was 
driven by protocol, but it is still interesting that the use of 
MMF was not associated with any sparing of the nephrotoxic 
agent, in this case, tacrolimus. . 
Two other points bear mentioning. The first concernS the 
incidence of PTDM, which is lower than in previous reports. 
93% 
95% 
85% 
92% 
44% 
7.5% 
1.6:+:0.9 
8.4:+:6 .. 0 
10.2:+:4 .. 5 
34% 
25% 
200:+:62 
8.5% 
0.9% 
21% 
9.3% 
4.7% 
O~P 
28% 
96% 94% 
98% 97% 
89% 87% 
93% 93% 
27%a 36% 
2.9% 5.3% 
1.7:+:0.7 1.6:+:0 .. 8 
9.0:+:7.1 8 .. 7:'::6.6 
10.1:+:4.2 10.1 :'::4.4 
39% 36% 
39% 32% 
192:+:46 196:+:55 
16.7% 12.5% 
~% 0.5% 
21% 21% 
4.7% 
1.2% 
3--2 
34% (2nd year; 12%) 
70% 
2.9% 
31% 
In the azathioprine trial, the initial and final incidence of 
PTDM was 18% and 9% (28), whereas in the American mul-
ticenter trial, it was 20% and 12% (29); in this trial, it was 7% 
and just under 3%. This suggests that, with more experience, 
it is possible to avoid this (largely reversible) complication. 
The second point concerns the incidence of cross-over. In the 
initial 6 months of this trial, some 48% of patients random-
ized to the triple-therapy arm had to discontinue MMF at one 
time or another, either because of gastrointestinal complica-
tions, principally diarrhea or gastritis, or hemitologic prob-
lems, principally neutropenia or thrombocytopenia. In gen-
eral, once MMF was discontinued, it was not resumed, 
although in a small number of patients (perhaps 10%), it was 
reintroduced at a low dose (250 mg once or twice daily). With 
separation ofthe MMF and tacrolimus dosages by 2-4 hr and 
early reduction of the MMF dosage at the first sign of toxic-
ity, the rate of cross-over declined to 12% during the second 
year of the trial. The higher levels and the greater area under 
the concentration curve of MMF with tacrolimus (30) cer-
tainly explain the need for lower dosages ofMMF, and in fact 
the average MMF dose at most recent follow-up was 57% of 
the starting dose. Not surprisingly, given the higher rate of 
rejection and increased severity of rejections in the double-
therapy arm, cross-over to triple therapy was required in 
some 28% of patients originally randomized to double ther-
apy. Cross-over to triple therapy was initiated in patients 
with a mild-moderate (Banff 1B) or greater rejection episode, 
or in patients with multiple episodes of mild acute rejection. 
The data from this randomized trial confirm those recently 
reported in a nonrandomized expe:r:ience (31), and suggest 
that the combination of tacrolimus and MMF is effective in 
patients undergoing renal transplantation, and that it is 
associated with a lower incidence of rejection than that seen 
in patients not receiving MMF. Short-term patient and graft 
survival are acceptable, although not different between the 
two groups. With increasing experience, cross-over from tri-
ple to double therapy has become less of a problem, ar.J.d the 
..... 
b 
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incidence of insulin-dependent PTDM has decreased. Future 
trials will look at the role of other agents, including induction 
with an anti-interleukin 2 monoclonal antibody (32-35), in 
combil,).ation with tacrolimus-based therapy,. and will be com-
pared with a tacrolimuslMMF-based regimen. 
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